Emerging therapeutic agents to lower lipoprotein (a) levels

Current Opinion in Lipidology

Volumn 23, Issue 6, 2012, Pages 560-568

  Kolski, Brian ^a   Tsimikas, Sotirios ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

apolipoprotein (a); cardiovascular disease; lipoprotein (a); oxidized phospholipids; treatment

Indexed keywords

ACETYLSALICYLIC ACID; AGER 733; ALIROCUMAB; ANACETRAPIB; ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN B100; CARNITINE; DALCETRAPIB; EPROTIROME; EZETIMIBE; FARNESOID X RECEPTOR; FIBROBLAST GROWTH FACTOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; INTERLEUKIN 8; KEXIN; LIPOPROTEIN A; LOMITAPIDE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; MIPOMERSEN; MONOCLONAL ANTIBODY; NICOTINIC ACID; SIMVASTATIN; SOBETIROME; SUBTILISIN; UNCLASSIFIED DRUG;

ABETALIPOPROTEINEMIA; APOPTOSIS; ATHEROSCLEROSIS; BINDING KINETICS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COMPETITIVE INHIBITION; ENVIRONMENTAL FACTOR; FAMILIAL HYPERCHOLESTEROLEMIA; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; KRINGLE DOMAIN; LIPID OXIDATION; LIPOPROTEIN METABOLISM; LIVER CELL; LOW DRUG DOSE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SYNTHESIS; PROTEIN TARGETING; REVIEW; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOSIS;

ANIMALS; ATHEROSCLEROSIS; HUMANS; HYPOLIPIDEMIC AGENTS; LIPOPROTEIN(A); MOLECULAR TARGETED THERAPY; RISK;

EID: 84870065743     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0b013e3283598d81     Document Type: Review

References (50)

1. Dube JB, Boffa MB, Hegele RA, Koschinsky ML. Lipoprotein(a): More interesting than ever after 50 years. Curr Opin Lipidol 2012; 23:133-140. Updated review of the role of Lp(a) in CV.D.
2. Faghihnia N, Tsimikas S, Miller ER, et al. Changes in lipoprotein(a), oxidized phospholipids, and LDL subclasses with a low-fat high-carbohydrate diet. J Lipid Res 2010; 51:3324-3330.
3. Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 2009; 361:2518-2528.
4. Li Y, Luke MM, Shiffman D, Devlin JJ. Genetic variants in the apolipoprotein(a) gene and coronary heart disease. Circ Cardiovasc Genet 2011; 4:565-573. This study reviews the consistent data of LPA SNP rs3798220 in mediating highplasma Lp(a) levels and increased risk of CV.D.
5. Tsimikas S, Clopton P, Brilakis ES, et al. Relationship of oxidized phospholipids on apolipoprotein B-100 particles to race/ethnicity, apolipoprotein(a) isoform size, and cardiovascular risk factors: results from the Dallas Heart Study. Circulation 2009; 119:1711-1719.
6. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 2009; 301:2331-2339.
7. The Emerging Risk Factors Collaboration. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009; 302:412-423.
8. Steyrer E, Durovic S, Frank S, et al. The role of lecithin: cholesterol acyltransferase for lipoprotein (a) assembly. Structural integrity of low density lipoproteins is a prerequisite for Lp(a) formation in human plasma. J Clin Invest 1994; 94:2330-2340.
9. Menzel HJ, Dieplinger H, Lackner C, et al. Abetalipoproteinemia with an ApoB-100-lipoprotein(a) glycoprotein complex in plasma. indication for an assembly defect. J Biol Chem 1990; 265:981-986.
10. Tsimikas S, Witztum JL, Miller ER, et al. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation 2004; 110:1406-1412. (Pubitemid 39238018)
11. Rader DJ, Mann WA, Cain W, et al. The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans. J Clin Invest 1995; 95:1403-1408.
12. Kraft HG, Lingenhel A, Raal FJ, et al. Lipoprotein(a) in homozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2000; 20:522-528. (Pubitemid 30086112)
13. Arai K, Orsoni A, Mallat Z, et al. Acute impact of apheresis on oxidized phospholipids in patients with familial hypercholesterolemia. J Lipid Res 2012; 53:1670-1678.
14. Erqou S, Thompson A, Di Angelantonio E, et al. Apolipoprotein(a) isoforms and the risk of vascular disease: Systematic review of 40 studies involving 58,000 participants. J Am Coll Cardiol 2010; 55:2160-2167.
15. Tsimikas S, Mallat Z, Talmud PJ, et al. Oxidation-specific biomarkers, lipoprotein (a), and risk of fatal and nonfatal coronary events. J Am Coll Cardiol 2010; 56:946-955.
16. Kiechl S, Willeit J, Mayr M, et al. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol 2007; 27:1788-1795. (Pubitemid 47207175)
17. Virani SS, Brautbar A, Davis BC, et al. Associations between lipoprotein(a) levels and cardiovascular outcomes in Black and white subjects: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2012; 125:241-249. Important study documenting Lp(a) is a risk factor for CVD in blacks, which was previously controversial.
18. Taleb A, Witztum JL, Tsimikas S. Oxidized phospholipids on apolipoprotein B-100(OxPL/apoB) containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events. Biomark Med 2011; 5:673-694. A comprehensive review documenting the role of OxPL as a key biological factor in the pathogenesis of Lp(a) atherogenicity and CVD risk. It describes both experimennal and clinical studies.
19. Bergmark C, Dewan A, Orsoni A, et al. A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. J Lipid Res 2008; 49:2230-2239.
20. Tsimikas S, Tsironis LD, Tselepis AD. New insights into the role of lipoprotein (a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease. Arterioscler Thromb Vasc Biol 2007; 27: 2094-2099. (Pubitemid 350287235)
21. Spence JD, Koschinsky ML. Mechanisms of lipoprotein(a) pathogenicity. Arterioscler Thromb Vasc Biol 2012; 32:1550-1551.
22. Seimon TA, Nadolski MJ, Liao X, et al. Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress. Cell Metab 2010; 12:467-482.
23. Jaeger BR, Richter Y, Nagel D, et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med 2009; 6:229-239.
24. Ky B, Burke A, Tsimikas S, et al. The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans. J Am Coll Cardiol 2008; 51:1653-1662. (Pubitemid 351626406)
25. Kostner GM,Gavish D, Leopold B, et al. HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. Circulation 1989; 80:1313-1319. (Pubitemid 19282521)
26. Choi SH, Chae A, Miller E, et al. Relationship between biomarkers of oxidized low-density lipoprotein, statin therapy, quantitative coronary angiography, and atheroma: volume observations from the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) study. J Am Coll Cardiol 2008; 52:24-32. (Pubitemid 351852928)
27. Rodenburg J, Vissers MN, Wiegman A, et al. Oxidized low-density lipoprotein in children with familial hypercholesterolemia and unaffected siblings: effect of pravastatin. J Am Coll Cardiol 2006; 47:1803-1810.
28. Boden WE, Probstfield JL, et al., AIM-HIGH-Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365:2255-2267.
29. Bruckert E, Labreuche J, Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 2010; 210:353-361.
30. Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010; 31:2844-2853.
31. Akaike M, Azuma H, Kagawa A, et al. Effect of aspirin treatment on serum concentrations of lipoprotein(a) in patients with atherosclerotic diseases. Clin Chem 2002; 48:1454-1459. (Pubitemid 34925781)
32. Tsimikas S, Bergmark C, Beyer RW, et al. Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. J Am Coll Cardiol 2003; 41:360-370. (Pubitemid 36164488)
33. Chasman DI, Shiffman D, Zee RY, et al. Polymorphism in the apolipoprotein(a) gene, plasma lipoprotein(a), cardiovascular disease, and low-dose aspirin therapy. Atherosclerosis 2009; 203:371-376.
34. Visser ME, Witztum JL, Stroes ES, Kastelein JJ. Antisense oligonucleotides for the treatment of dyslipidaemia. Eur Heart J 2012; 33:1451-1458. A comprehensive review on the role of antisense oigonucleotides in lowering LDL and Lp(a) levels.
35. Tsimikas S, Witztum J, Catapano A. Effect of mipomersen on lipoprotein(a) in patients with hypercholesterolemia across four phase III studies. J Am Coll Cardiol 2012; 59:E1494.
36. Merki E, Graham MJ, Mullick AE, et al. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice. Circulation 2008; 118:743-753.
37. Merki E, Graham M, Taleb A, et al. Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice. J Am Coll Cardiol 2011; 57:1611-1621. This study describes the potent Lp(a) lowering effect of a specific ASO to apo(a) and may define a novel specific therapy to lower Lp(a) in humans.
38. Cohen JC, Boerwinkle E, Mosley TH Jr., Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006; 354:1264-1272.
39. Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012; 366:1108-1118.
40. McKenney JM, Koren MJ, Kereiakes DJ, et al. Safety andefficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol 2012; 59:2344-2353. This US multicenter randomized trial compared PCSK9 inhibitor with placebo in patients already receiving statin therapy, showing significant plasma Lp(a) lowering.
41. Cannon CP, Shah S, Dansky HM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010; 363:2406-2415.
42. Samaha FF, McKenney J, Bloedon LT, et al. Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia. Nat Clin Pract Cardiovasc Med 2008; 5:497-505.
43. Milionis HJ, Efstathiadou Z, Tselepis AD, et al. Lipoprotein (a) levels and apolipoprotein (a) isoform size in patients with subclinical hypothyroidism: effect of treatment with levothyroxine. Thyroid 2003; 13:365-369. (Pubitemid 36588521)
44. Ladenson PW, Kristensen JD, Ridgway EC, et al. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N Engl J Med 2010; 362:906-916.
45. Grover GJ, Egan DM, Sleph PG, et al. Effects of the thyroid hormone receptor agonist GC-1 on metabolic rate and cholesterol in rats and primates: selective actions relative to 3,5,3'-triiodo-L-thyronine. Endocrinology 2004; 145: 1656-1661. (Pubitemid 38402372)
46. Chennamsetty I, Claudel T, Kostner KM, et al. Farnesoid X receptor represses hepatic human APOA gene expression. J Clin Invest 2011; 121:3724-3734.
47. Chennamsetty I, Claudel T, Kostner KM, et al. FGF19 signaling cascade suppresses APOA gene expression. Arterioscler Thromb Vasc Biol 2012; 32:1220-1227. This study describes a potential mechnaism through which apo(a) expression may be inhibited and suggest a new target of therapy to lower Lp(a).
48. Schultz O, Oberhauser F, Saech J, et al. Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases. PLoS One 2010; 5:e14328.
49. Berthold HK, Laudes M, Krone W, Gouni-Berthold I. Association between the interleukin-6 promoter polymorphism 174G/C and serum lipoprotein(a) concentrations in humans. PLoS One 2011; 6:e24719.
50. Hall JL, Tsimikas S. Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies. J Am Coll Cardiol 2012; 60:716-721.